Archives
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
To our knowledge BAY has not progressed
2023-02-17

To our knowledge, BAY 60-6583 has not progressed to clinical development and remains to be the only ADORA2B agonist that has been developed.33, 34 Further development of similar compounds would be beneficial in future fibrosis research. One of the limitations of our study is being limited to in vit
There are however concerns of
2023-02-13

There are however, concerns of potential side-effects that should also be taken into account. Even though some studies pointed towards a potentially greater radiosensitising effect in p53-deficient tumours, ATM inhibition radiosensitises sulconazole in general, which raises the concern of normal ti
There are no studies documented the
2023-02-13

There are no studies documented the role of RAS in the differentiation of MSCs into IPCs but there are previous studies indicating that Ang II receptors exhibit opposing actions on MSCs differentiation, into other cell types rather than IPCs. The blockade of AT2R was reported to suppress MSCs differ
br Eprosartan The AT R antagonist eprosartan
2023-02-13

Eprosartan The AT1R antagonist eprosartan is approved for the treatment of essential Cerulenin and may be administered using a convenient once-daily regimen. The drug is a well-tolerated and effective antihypertensive agent with benefit in the secondary prevention of cerebrovascular events, indep
LCL161 Recently the FDA approved the first blood based test
2023-02-13

Recently, the FDA approved the first blood-based test for the detection of EGFR mutations in non-small cell lung cancer patients (http://www.fda.gov) (Voelker, 2016). This allows detection of specific, recurrent mutations, which can help the selection of the patients that could benefit from Erlotini
In past Zebra fish Danio
2023-02-13

In past, Zebra fish (Danio rerio) has emerged as a suitable model for early vertebrate development, and a number of targeted mutations in the zebrafish genome led to phenotypic alterations that resemble human diseases [34]. A 12-LOX in Zebra fish has been cloned and knock down of this zf12-LOX enzym
We found evidence of the interaction between AR and hemiacet
2023-02-13

We found evidence of the interaction between AR and hemiacetals by evaluating the effect of glucose on l-idose reduction. l-idose was recently proposed as the best AR substrate able to mimic glucose [38]. This aldose is structurally very closely related to d-glucose, from which it differs only in th
Glucose Uptake Fluorometric Assay Kit receptor The AhR molec
2023-02-13

The AhR molecule is composed of multiple functional domains [38]. In the N-terminal end, the AhR contains bHLH domain which is involved in DNA binding, dimerization with ARNT and association with chaperone proteins. The PAS domain, which is situated next to the bHLH domain consists of two structural
Since non lipoprotein derived free cholesterol is recycled f
2023-02-13

Since non-lipoprotein-derived free cholesterol is recycled from the plasma membrane through the endosomal system through receptor-independent mechanisms, we wanted to determine whether ABCA2 could alter the trafficking of this source of free cholesterol. Our approach was to measure the effect of mob
If overexpression of ADK is
2023-02-13

If overexpression of ADK is sufficient to induce spontaneous seizures, then reduction of ADK in engineered mice should prevent epileptogenesis. The generation of mice with moderately reduced levels of ADK in brain rather than complete ADK deficiency seems to be essential, since several lines of evid
br Conclusion There have been multiple
2023-02-13

Conclusion There have been multiple clinical trials and pre-clinical studies that have tested the utility of 5ARIs in treating prostate disease, as summarized in Fig. 1. Inhibiting androgen action through the use of finasteride and dutasteride has been established as a valuable resource for physi
The first rationally designed dual mPGES LO inhibitor was
2023-02-13

The first rationally designed dual mPGES-1/5-LO inhibitor was reported in 2008 and represents a structural derivative of pirinixic inhibitor chemistry - a synthetic agonist of PPARα with lipid-lowering properties (Koeberle et al., 2008b). Further α-alkyl- and α-aryl-substituted derivatives have bee
The anorexic effect observed when
2023-02-13

The anorexic effect observed when AR231630 is infused into the VTA could be the result of the DA release inhibition, as previously described [11]. However, there is also a hedonic aspect in feeding that possibly involves dopaminergic mechanisms of reward. Helm et al. showed a functional link between
Among the AXL positive tumors
2023-02-10

Among the AXL-positive tumors that we screened, the TNBC cell line MDA-MB-231 showed the highest AXL expression level. Additionally, AXL protein levels were higher in TNBC patient samples than in other breast cancers. Considering the difficulty of, and the urgent need for, effective treatments of TN
BMS 195614 In the present study we sought
2023-02-10

In the present study we sought to decipher the role of ATP-citrate lyase and of the mitochondrial NADH-dependent Mae in the oleaginous yeast Y. lipolytica. Indeed, although this yeast is one of the major models for lipid metabolism, the function of these enzymes is still not clear. As the study of t
8053 records 351/537 page Previous Next First page 上5页 351352353354355 下5页 Last page